Projected Impact of Omidubicel-onlv on Racial/Ethnic Disparities in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Outcomes in Hematologic Malignancies
Introduction In a phase III clinical trial (NCT02730299), omidubicel-onlv, a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy, showed rapid hematopoietic and immune recovery compared with standard umbilical cord blood (UCB) transplant across all racial/ethnic groups. Methods A decision-tree model was used to project the effect of omidubicel-onlv availability on addressing health disparities in allogeneic hematopoietic cell transplantation (allo-HCT) access and outcomes for patients with hematologic malignancies. The model used a hypothetical population of 10,000 allo-HCT-eligible US adults, for whom matched related donors were not available. Patients received matched or mismatched unrelated donor, haploidentical, UCB transplant, or no transplant. Scenarios with omidubicel-onlv use of 0% (status quo), 10%, 15%, 20%, and 30% were modeled on the basis of proportional reductions in other allo-HCT sources or no transplant by racial/ethnic group. Results Increased omidubicel-onlv use was associated with a higher proportion of patients undergoing allo-HCT, decreased time to allo-HCT, decreased 1-year non-relapse mortality, and increased 1-year overall survival, particularly among racial minorities. In the scenario modeling 20% omidubicel-onlv use, the proportion of Black patients receiving allo-HCT increased by 129%; increases were also observed in Asian (64%), Hispanic (45%), and other (42%) patient groups. Modeled time to allo-HCT improved among transplanted patients (23%) from 11.4 weeks to 8.8 weeks. One-year OS in the overall population increased by 3%, with improvements ranging from 3% for White patients to 5% for Black patients. Conclusion This study demonstrates that broad access to omidubicel-onlv could increase access to allo-HCT and improve outcomes for patients, with the greatest benefits seen among racial/ethnic minority groups. Graphical Abstract.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
---|---|
Enthalten in: |
Advances in therapy - 41(2024), 4 vom: 01. März, Seite 1637-1651 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Khera, Nandita [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Allogeneic hematopoietic cell transplant |
---|
Anmerkungen: |
© The Author(s) 2024 |
---|
doi: |
10.1007/s12325-023-02771-z |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR055270166 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | SPR055270166 | ||
003 | DE-627 | ||
005 | 20240325061004.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240325s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12325-023-02771-z |2 doi | |
035 | |a (DE-627)SPR055270166 | ||
035 | |a (SPR)s12325-023-02771-z-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
100 | 1 | |a Khera, Nandita |e verfasserin |4 aut | |
245 | 1 | 0 | |a Projected Impact of Omidubicel-onlv on Racial/Ethnic Disparities in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Outcomes in Hematologic Malignancies |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s) 2024 | ||
520 | |a Introduction In a phase III clinical trial (NCT02730299), omidubicel-onlv, a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy, showed rapid hematopoietic and immune recovery compared with standard umbilical cord blood (UCB) transplant across all racial/ethnic groups. Methods A decision-tree model was used to project the effect of omidubicel-onlv availability on addressing health disparities in allogeneic hematopoietic cell transplantation (allo-HCT) access and outcomes for patients with hematologic malignancies. The model used a hypothetical population of 10,000 allo-HCT-eligible US adults, for whom matched related donors were not available. Patients received matched or mismatched unrelated donor, haploidentical, UCB transplant, or no transplant. Scenarios with omidubicel-onlv use of 0% (status quo), 10%, 15%, 20%, and 30% were modeled on the basis of proportional reductions in other allo-HCT sources or no transplant by racial/ethnic group. Results Increased omidubicel-onlv use was associated with a higher proportion of patients undergoing allo-HCT, decreased time to allo-HCT, decreased 1-year non-relapse mortality, and increased 1-year overall survival, particularly among racial minorities. In the scenario modeling 20% omidubicel-onlv use, the proportion of Black patients receiving allo-HCT increased by 129%; increases were also observed in Asian (64%), Hispanic (45%), and other (42%) patient groups. Modeled time to allo-HCT improved among transplanted patients (23%) from 11.4 weeks to 8.8 weeks. One-year OS in the overall population increased by 3%, with improvements ranging from 3% for White patients to 5% for Black patients. Conclusion This study demonstrates that broad access to omidubicel-onlv could increase access to allo-HCT and improve outcomes for patients, with the greatest benefits seen among racial/ethnic minority groups. Graphical Abstract | ||
650 | 4 | |a Allogeneic hematopoietic cell transplant |7 (dpeaa)DE-He213 | |
650 | 4 | |a Healthcare equity |7 (dpeaa)DE-He213 | |
650 | 4 | |a Hematologic malignancies |7 (dpeaa)DE-He213 | |
650 | 4 | |a Omidubicel-onlv |7 (dpeaa)DE-He213 | |
700 | 1 | |a Edwards, Marie Louise |4 aut | |
700 | 1 | |a Song, Yan |4 aut | |
700 | 1 | |a Sun, Rochelle |4 aut | |
700 | 1 | |a Manghani, Rocio |4 aut | |
700 | 1 | |a Shin, Heayoung |4 aut | |
700 | 1 | |a Simantov, Ronit |4 aut | |
700 | 1 | |a Signorovitch, James |4 aut | |
700 | 1 | |a Sivaraman, Smitha |4 aut | |
700 | 1 | |a Gergis, Usama |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d Springer Healthcare, 2000 |g 41(2024), 4 vom: 01. März, Seite 1637-1651 |w (DE-627)SPR024919926 |w (DE-600)2421646-X |x 1865-8652 |7 nnns |
773 | 1 | 8 | |g volume:41 |g year:2024 |g number:4 |g day:01 |g month:03 |g pages:1637-1651 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12325-023-02771-z |z kostenfrei |3 Volltext |
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 41 |j 2024 |e 4 |b 01 |c 03 |h 1637-1651 |